21:46 , Dec 15, 2017 |  BC Week In Review  |  Clinical News

Cantargia reports Phase I/IIa data for cancer candidate CAN04

In October, Cantargia AB (SSE:CANTA) reported data from 1 patient in the Phase I/IIa CANFOUR trial showing that once-weekly IV CAN04 led to no serious adverse events. The first part of the open-label, European trial...
07:00 , Oct 31, 2016 |  BC Week In Review  |  Financial News

Cantargia completes warrant exercise

Cantargia AB (SSE:CANTA), Lund, Sweden  Business: Cancer  Date completed: 2016-10-24  Type: Warrant exercise  Raised: SEK24.6 million ($2.8 million)  Shares: 3.2 million  Price: SEK7.60  Shares after offering: 20.9 million  Investor: Existing investors ...
08:00 , Nov 19, 2015 |  BC Innovations  |  Product R&D

A solid move

Following its IPO in March, Cantargia AB is shifting the focus of its lead program from cancers of the blood to solid tumors. After finding its anti-IL-1RAP mAb affects the tumor microenvironment as well as...
07:00 , Sep 24, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Interleukin-1 receptor accessory protein (IL-1RAP)

Cancer INDICATION: Acute myelogenous leukemia (AML) In vitro and mouse studies suggest anti- IL-1RAP antibodies could help treat AML. IL-1RAP is expressed by 80% of AML cells and correlates with poor prognosis. In primary AML...
07:00 , Apr 6, 2015 |  BioCentury  |  Finance

Fundamental rally

2Q15 Financial Markets Preview Following three consecutive years of spectacular returns and a solid first quarter, bankers and buysiders remain confident that large caps will continue to deliver on sales and smaller companies will continue...
08:00 , Jan 26, 2015 |  BC Week In Review  |  Financial News

Cantargia proposes IPO

Cantargia AB , Lund, Sweden   Business: Cancer   Date announced: 2015-01-16   Type: IPO   To be raised: Up to SEK44.1 million ($5.4 million)   Shares: 5.8 million   Price: SEK7.60   Note: Cantargia...
07:00 , Jun 30, 2014 |  BC Week In Review  |  Company News

Cantargia AG management update

Cantargia AG , Lund, Sweden   Business: Cancer   Hired: Goeran Forsberg as CEO, formerly CBO of Active Biotech AB ; he replaces interim CEO Anki Malmborg Hager  ...
07:00 , Jun 30, 2014 |  BC Week In Review  |  Financial News

Cantargia completes venture financing

Cantargia AB , Lund, Sweden   Business: Cancer   Date completed: 2014-06-17   Type: Venture financing   Raised: SEK20 million ($3 million)   Investor: LU Bioscience  ...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Financial News

Cantargia financial update

Cantargia raised an additional SEK7 million ($1 million) in a series A round, bringing the total raised to SEK11.3 million ($1.7 million). Lund University Bioscience AB and Sunstone Capital participated in the round. The company...
08:00 , Jan 14, 2013 |  BC Week In Review  |  Company News

Zealand Pharma management update

Zealand Pharma A/S (CSE:ZEAL), Glostrup, Denmark   Business: Endocrine/Metabolic, Cardiovascular, Gastrointestinal   Hired: Agneta Svedberg as COO, effective Feb.1, formerly CEO of Cantargia AB ; she succeeds John Hyttel, who is retiring  ...